Expanding Global Access to ProSense®
This recent approval significantly enhances the worldwide availability of IceCure's ProSense® technology. It reflects the company's ongoing commercial momentum, especially after obtaining marketing authorization from the U.S. Food and Drug Administration (FDA) for low-risk breast cancer treatment options.
ProSense® Cryoablation System Details
IceCure Medical Ltd. (NASDAQ: ICCM) has been a pioneer in developing cryoablation technology. This innovative method targets tumors by using extremely low temperatures to destroy tissue. The ProSense® system and its associated cryoprobes have received registration and approval from Swissmedic, the Swiss Agency for Therapeutic Products, specifically for the treatment of malignant and benign tumors in the breast, lung, liver, kidney, and musculoskeletal regions.
Statements from Leadership
“The approval in Switzerland contributes to our strong regulatory and commercial trajectory,” commented Eyal Shamir, IceCure's Chief Executive Officer. He further stated that entering another crucial European market will allow IceCure to increase the adoption of ProSense® as a viable alternative to traditional surgical procedures.
The Impact of Swiss Approval
Switzerland is renowned for its commitment to healthcare innovation, offering state-of-the-art medical technologies to support high-quality patient care. The country's healthcare expenditure is projected to hit approximately $120 billion, reflecting its prioritization of health services. This market's demand for advanced treatments positions ProSense® favorably among healthcare practitioners.
Understanding ProSense® Cryoablation
The ProSense® Cryoablation System stands out as the first and only device approved by the FDA for local treatment of low-risk breast cancer, specifically designed for women aged 70 and older who may not be suitable candidates for surgical options. This system utilizes liquid nitrogen to create significant lethal zones around tumors, making it effective for both benign and cancerous lesions.
Benefits of ProSense® Technology
One of the remarkable advantages of ProSense® is the reduction in patient recovery time and discomfort compared to traditional surgical methods. Additionally, its compact and transportable design allows for convenient and quick office procedures, giving patients faster access to care without the need for extensive hospital visits.
About IceCure Medical
IceCure Medical specializes in the development and marketing of advanced cryoablation therapy systems. Their focus is on creating minimally invasive solutions for tumor destruction across various cancers, primarily targeting the breast, kidney, bone, and lung cancer markets. The ProSense® system is already available and marketed globally in multiple regions, including the U.S., Europe, and Asia.
Contact Information
For inquiries, interested parties can reach out via email at investors@icecure-medical.com. Michael Polyviou is available at 732-232-6914 for further assistance.
Frequently Asked Questions
What is the ProSense® system used for?
The ProSense® system is used for minimally invasive treatment of tumors through cryoablation, which effectively destroys malignant and benign tissues.
How does cryoablation work?
It utilizes extremely low temperatures through liquid nitrogen to create large lethal zones around tumors, ensuring maximum destruction of targeted tissues.
What types of cancer can ProSense® treat?
ProSense® is approved for treating breast, lung, liver, kidney, and musculoskeletal cancers.
Why is Swiss approval significant?
Switzerland is a leader in healthcare innovation, and this approval opens additional avenues for IceCure to expand its market presence in Europe.
How can I contact IceCure Medical?
Interested individuals can contact IceCure via email at investors@icecure-medical.com or call Michael Polyviou at 732-232-6914.
